XTANDI 40 MG
ENZALUTAMIDE : 40 MG · DIN 02407329 · ASTELLAS PHARMA CANADA INC
Health Canada status: MARKETED
What is XTANDI?
XTANDI 40 MG contains ENZALUTAMIDE : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02407329, held by ASTELLAS PHARMA CANADA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Jun-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XTANDI used for?
Treatment of nmCSPC with high-risk BCR, metastatic CSPC, non-metastatic CRPC, and metastatic CRPC (chemotherapy-naïve or post-docetaxel).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02407329 |
|---|---|
| Brand name | XTANDI |
| Generic / active ingredient | ENZALUTAMIDE : 40 MG |
| Manufacturer | ASTELLAS PHARMA CANADA INC |
| Strength | 40 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L02BB04 ENZALUTAMIDE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Jun-2013 |
| Original market date | 2013-06-07 00:00:00 |
How is it administered?
160 mg (four 40 mg capsules) once daily. Swallow whole; do not chew, dissolve, or open. May be taken with or without food. Dose adjustments required for strong CYP2C8 inhibitors.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Do not use beyond expiration date indicated on the package. (Specific temperature range not provided in the provided text snippet).
How is it supplied?
Bottles of 120 capsules; Blister Cartons of 112 capsules (4 capsules per cavity, 28 capsules per wallet).
Contraindications
Hypersensitivity to enzalutamide or any ingredient; women who are or may become pregnant; women who are lactating.
Warnings and precautions
Seizures, Posterior Reversible Encephalopathy Syndrome (PRES), ischemic heart disease, hypertension, falls/fractures, and mental impairment. Strong inducer of CYP3A4.
Who else supplies ENZALUTAMIDE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ENZALUTAMIDE appears in 33 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.